Hemostemix (CVE:HEM) Trading Up 34.5% – Time to Buy?

Shares of Hemostemix Inc. (CVE:HEM) traded up 34.5% on Thursday . The stock traded as high as C$0.20 and last traded at C$0.20. 143,687 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 515,150 shares. The stock had previously closed at C$0.15.

Hemostemix Stock Up 31.0 %

The stock’s fifty day moving average is C$0.20 and its 200 day moving average is C$0.12. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The company has a market capitalization of C$27.69 million, a P/E ratio of -5.54 and a beta of 0.20.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.